PMID- 21123160
OWN - NLM
STAT- MEDLINE
DCOM- 20110317
LR  - 20220409
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 22
IP  - 5
DP  - 2010 Oct
TI  - Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum 
      beta-lactamase-producing Escherichia coli-related complicated lower urinary tract 
      infection.
PG  - 355-7
AB  - The aim of this observational prospective study was to compare the effect of 
      fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in 
      the treatment of extended-spectrum beta-lactamase (ESBL)-producing Escherichia 
      coli-related complicated lower urinary tract infection (CLUTI). Inclusion 
      criteria were: patients who were aged >18 yr with dysuria or problems with 
      frequency or urgency in passing urine; those with >20 leukocytes/mm(3) in urine 
      microscopy and culture-proven ESBL-producing carbapenem or FT-sensitive E. coli 
      in the urine (>10(5) cfu/mm(3)); no leukocytosis or fever; and who were treated with 
      ft (oral 3 g sachet x 1 every other night, three times) or carbapenems between 
      march 2005 and January 2006 in our outpatient clinic and hospital. A total of 47 
      CLUTI attacks in 47 patients (27 FT group, 20 carbapenem group) were observed 
      prospectively. Clinical and microbiological success in the carbapenem and ft 
      groups was similar (19/20 vs 21/27 and 16/20 vs 16/27 p>0.05). Drug acquisition 
      costs were significantly lower in the FT group (p<0.001). Although it is not a 
      randomized controlled study, these data show that ft may be a suitable, effective 
      and cheap alternative in the treatment of ESBL-producing E. coli-related CLUTI.
FAU - Senol, S
AU  - Senol S
AD  - Celal Bayar University, Department of Infectious Diseases and Clinical 
      Microbiology, Manisa, Turkey.
FAU - Tasbakan, M
AU  - Tasbakan M
FAU - Pullukcu, H
AU  - Pullukcu H
FAU - Sipahi, O R
AU  - Sipahi OR
FAU - Sipahi, H
AU  - Sipahi H
FAU - Yamazhan, T
AU  - Yamazhan T
FAU - Arda, B
AU  - Arda B
FAU - Ulusoy, S
AU  - Ulusoy S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carbapenems)
RN  - 2N81MY12TE (Fosfomycin)
RN  - EC 3.5.2.6 (beta-Lactamases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Carbapenems/economics/*therapeutic use
MH  - Drug Resistance, Bacterial
MH  - Escherichia coli/*drug effects/enzymology
MH  - Escherichia coli Infections/*drug therapy/microbiology
MH  - Female
MH  - Fosfomycin/economics/*therapeutic use
MH  - Humans
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Prospective Studies
MH  - Urinary Tract Infections/*drug therapy/microbiology
MH  - Young Adult
MH  - beta-Lactamases/*metabolism
EDAT- 2010/12/03 06:00
MHDA- 2011/03/18 06:00
CRDT- 2010/12/03 06:00
PHST- 2010/12/03 06:00 [entrez]
PHST- 2010/12/03 06:00 [pubmed]
PHST- 2011/03/18 06:00 [medline]
AID - 10.1179/joc.2010.22.5.355 [doi]
PST - ppublish
SO  - J Chemother. 2010 Oct;22(5):355-7. doi: 10.1179/joc.2010.22.5.355.